Strategic Advisors LLC Has $2.14 Million Holdings in Danaher Co. (NYSE:DHR)

Strategic Advisors LLC raised its position in Danaher Co. (NYSE:DHR) by 168.3% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 9,317 shares of the conglomerate’s stock after acquiring an additional 5,845 shares during the period. Strategic Advisors LLC’s holdings in Danaher were worth $2,139,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in DHR. Kovack Advisors Inc. boosted its holdings in Danaher by 3.4% during the 3rd quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock valued at $346,000 after acquiring an additional 41 shares during the period. Waypoint Capital Advisors LLC raised its position in Danaher by 0.9% during the 3rd quarter. Waypoint Capital Advisors LLC now owns 4,520 shares of the conglomerate’s stock valued at $1,257,000 after purchasing an additional 42 shares during the last quarter. Gilbert & Cook Inc. raised its position in Danaher by 2.5% during the 4th quarter. Gilbert & Cook Inc. now owns 1,749 shares of the conglomerate’s stock valued at $401,000 after purchasing an additional 42 shares during the last quarter. Grimes & Company Inc. raised its position in Danaher by 0.6% during the 4th quarter. Grimes & Company Inc. now owns 7,390 shares of the conglomerate’s stock valued at $1,696,000 after purchasing an additional 43 shares during the last quarter. Finally, Harbour Investments Inc. raised its position in Danaher by 3.0% during the 3rd quarter. Harbour Investments Inc. now owns 1,531 shares of the conglomerate’s stock valued at $426,000 after purchasing an additional 45 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Performance

DHR stock opened at $206.66 on Monday. The company has a market cap of $149.26 billion, a P/E ratio of 39.14, a price-to-earnings-growth ratio of 2.68 and a beta of 0.83. Danaher Co. has a 1 year low of $196.80 and a 1 year high of $281.70. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. The stock’s fifty day moving average price is $229.53 and its 200-day moving average price is $249.33.

Danaher (NYSE:DHR) last announced its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period in the previous year, the company posted $2.09 EPS. On average, equities analysts forecast that Danaher Co. will post 7.67 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Friday, December 27th were given a dividend of $0.27 per share. The ex-dividend date of this dividend was Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.52%. Danaher’s dividend payout ratio (DPR) is presently 20.45%.

Analysts Set New Price Targets

DHR has been the subject of a number of recent analyst reports. Guggenheim initiated coverage on Danaher in a research report on Thursday, December 19th. They set a “buy” rating and a $275.00 price target for the company. Barclays lowered their price target on Danaher from $275.00 to $240.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. TD Cowen increased their target price on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research report on Wednesday, October 23rd. Stifel Nicolaus increased their target price on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research report on Wednesday, October 23rd. Finally, Citigroup decreased their target price on Danaher from $285.00 to $265.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. Seven equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $278.00.

Insider Activity

In related news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 11.10% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.